Ronald C. Renaud's most recent trade in Upstream Bio Inc. was a trade of 17,096 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Upstream Bio Inc. | Ronald C. Renaud | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 17,096 | 17,096 | - | - | Stock Option (Right to Buy) | |
| Upstream Bio Inc. | Ronald C. Renaud | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2024 | 17,096 | 17,096 | - | - | Stock Option (Right to Buy) | |
| Cerevel Therapeutics Holdi... | Renaud C. Ronald | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 284,023 | 284,023 | - | - | Restricted Stock Units | |
| Cerevel Therapeutics Holdi... | Ronald C. Renaud | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 160,452 | 0 | - | - | Restricted Stock Units | |
| Cerevel Therapeutics Holdi... | Renaud C. Ronald | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 160,452 | 160,452 | - | - | Common Stock | |
| Cerevel Therapeutics Holdi... | Ronald C. Renaud | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 23.96 per share. | 03 Aug 2023 | 83,857 | 83,857 | - | 24.0 | 2,008,811 | Common Stock |
| Atara Biotherapeutics Inc | Ronald C. Renaud | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 31,500 | 31,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Ronald C. Renaud | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,500 | 31,500 (0%) | 0% | 0 | Common Stock | |
| Ikena Oncology Inc | Ronald C. Renaud | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Ikena Oncology Inc | Ronald C. Renaud | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 13,419 | 13,419 | - | - | Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Ronald C. Renaud | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Ronald C. Renaud | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,000 | 11,000 (0%) | 0% | 0 | Common Stock |